Publisher: BizWire Express


In the Media

VERU-111 Suppresses Key Cytokines Responsible for Severe Acute Respiratory Distress Syndrome in COVID-19

In the Media Icon

Veru Inc. (NASDAQ: VERU), an oncology and urology biopharmaceutical company with a focus on developing novel medicines for the management of prostate cancer, today announced that it has confirmed in an in vitro study that VERU-111 has anti-inflammatory action against the key cytokines involved in the cytokine storm triggered by the SARS-CoV-2 infection.   August… Read More


In the Media

Accumen Develops New Channels for Critical COVID-19 Supplies and Recovery Resources for Hospitals and Health Systems

In the Media Icon

Accumen Inc. is helping healthcare get better, faster. Today the company announced the launch of its COVID-19 Resource Center, which provides practical tools for hospital laboratories, supply chain, blood management, and imaging departments supporting patient care during this pandemic.